Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Selzentry Advisory Committee To Weigh Virologic Resistance Vs. Adverse Events

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer wants to expand the indication of its HIV drug to treatment-naive patients, but FDA wants the panel's advice on what the standards for such a claim should be.
Advertisement

Related Content

Selzentry Patient Population Needs Further Definition, Advisory Panel Urges
Selzentry Patient Population Needs Further Definition, Advisory Panel Urges
Selzentry Faces Assay Challenge Even After Advisory Committee Thumbs Up
Selzentry Faces Assay Challenge Even After Advisory Committee Thumbs Up
Reanalyzed MERIT Data Suggests Selzentry Efficacy Matches HIV Standard Of Care
Pfizer’s Selzentry Wins FDA Approval For HIV
Pfizer’s Selzentry Wins FDA Approval For HIV

Topics

Advertisement
UsernamePublicRestriction

Register

PS068701

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel